Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2Completed 2

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Mantle-Cell 13Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 8Waldenstrom Macroglobulinemia 6Lymphoma 6Recurrence 4Lymphoma, B-Cell 4Neoplasms 2Leukemia 2Lymphoma, Non-Hodgkin 1Lymphohistiocytosis, Hemophagocytic 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

venetoclax 21Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Dexamethasone 5Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Inotuzumab Ozogamicin 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2ponatinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia × zanubrutinib × Clear all
NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06520098 2025-10-14

Benefit VA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡